StudyFinder
The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction with VISITAG SURPOINT Module for the treatment of symptomatic drug refractory paroxysmal atrial fibrillation (A nested sub-study of REAL AF registry)
Status: Recruiting
The purpose of this research is to provide additional information about safety and effectiveness of the VISITAG SURPOINT Module with external processing unit (EPU) when used with QDOT Micro? System.
Sex: Male or Female
Age: 18 years and over
Healthy Volunteers:
Inclusion Criteria:
• 18 years of age or older
• Symptomatic atrial fibrillation refractory to antiarrhythmic drugs (AADs)
• Scheduled or have undergone an atrial fibrillation ablation usint the QDOT Micro? System
Exclusion Criteria:
• Patients who have undergone catheter ablation for atrial fibrillation (PVI, roof line, posterior wall ablation...)
• Persistent or long-standing persistent atrial fibrillation
Interventions:
Drug/Device: QDOT Micro? System
Conditions:
Atrial Fibrillation
Keywords:
Ablation, Anti-Arrhythmic medications, Atrial Fibrillation
Contact(s): Briita Wanhala - bwanhal1@hfhs.org
Principal Investigator: Arfaat Khan
Principal Investigator ID: akhan2@hfhs.org
Phase: N/A
See this study on ClinicalTrials.gov